Semaglutide and Tirzepatide are GLP-1 (and GIP) receptor agonists studied for weight management, glycemic control, and metabolic optimization. Physician-reviewed. Prescription required.
Semaglutide is a long-acting synthetic analog of GLP-1 used for treatment of type 2 diabetes and obesity. Its mechanisms center on activation of GLP-1 receptors throughout the pancreas, gastrointestinal tract, brain, and other tissues. Tirzepatide is an incretin-based peptide drug that works through dual activation of the GLP-1 receptor and GIP receptor — producing synergistic effects on glucose metabolism, appetite regulation, gastric emptying, and energy balance.
Both compounds work through incretin-based mechanisms to enhance insulin secretion, suppress glucagon, slow gastric emptying, and reduce appetite through central nervous system pathways. Tirzepatide's dual agonism produces additional metabolic benefits through GIP receptor activation. Individual outcomes may differ. This protocol is not intended to diagnose, treat, cure, or prevent any disease.
| Mechanism | Biological Effect |
|---|---|
| GLP-1 receptor agonism | Enhanced incretin signaling |
| Glucose-dependent insulin release | Lower blood glucose |
| Glucagon suppression | Reduced hepatic glucose output |
| Slowed gastric emptying | Reduced post-meal glucose spikes |
| Central appetite suppression | Reduced food intake |
| β-cell protection | Sustained insulin production |
| Mechanism | Biological Effect |
|---|---|
| Dual GLP-1+GIP receptor agonism | Enhanced incretin signaling |
| Glucose-dependent insulin secretion | Better glycemic control |
| Glucagon suppression | Reduced hepatic glucose output |
| Slowed gastric emptying | Lower postprandial glucose |
| Appetite suppression | Reduced caloric intake |
| β-cell protection | Sustained insulin production |
Your physician will determine eligibility based on your complete health intake. The following profiles are commonly associated with Semaglutide / Tirzepatide protocol candidates in clinical practice:
Weight Management
Individuals with BMI ≥27 with comorbidities or ≥30, seeking physician-supervised GLP-1 therapy.
Type 2 Diabetes
Individuals with T2D seeking GLP-1-based glycemic control under physician supervision.
Cardiovascular Risk Reduction
Individuals with metabolic syndrome or cardiovascular risk factors where GLP-1 therapy may be clinically appropriate.
Metabolic Optimization
Individuals pursuing physician-reviewed metabolic health optimization as part of a comprehensive longevity protocol.
Determine your candidacy
A physician will review your intake and make eligibility determination within 24–48 hours.
All outcome language below reflects what has been observed in clinical and preclinical settings. Individual outcomes may differ significantly. These are not guarantees.
Dosing is determined individually by your assigned physician. The following represents typical ranges discussed in clinical literature. Do not self-administer or adjust dosing without physician guidance.
Typical Range
Semaglutide: 0.25–2.4 mg/week; Tirzepatide: 2.5–15 mg/week
Administration
Subcutaneous injection (weekly)
Duration
Ongoing with periodic reassessment
Frequency
Once weekly (physician-determined)
These ranges are indicative only. Your physician will prescribe the specific dose and schedule appropriate for your clinical profile.
Physician consultation — Virtual intake review and protocol consultation with your assigned NP/MD
Valid prescription — Issued by your attending physician upon protocol approval
Pharmacy-dispensed compound — Dispensed by our licensed 503A compounding pharmacy partner
Follow-up check-in — Physician review at protocol midpoint; reorder pathway established
Your physician will review your complete health history before determining eligibility. The following are commonly reviewed clinical considerations.
Begin your Semaglutide / Tirzepatide protocol.
Complete your intake. Physician review within 24–48 hours.
Physician-reviewed. Pharmacy-dispensed. Prescription required before any order is fulfilled.
Prescription required. Results may vary. Individual outcomes may differ.
Verum Health semaglutide starts at $80/vial for starting doses and scales to $350/month for higher maintenance doses — a fraction of brand-name Ozempic or Wegovy pricing.
Most patients notice reduced appetite within 1-2 weeks. Meaningful weight loss typically begins at weeks 4-8. Full results develop over 3-6 months.
Yes. Semaglutide compounded by a licensed 503A pharmacy with a valid physician prescription is fully legal in the United States.
Verum Health serves 31 states plus DC including Texas, Florida, New York, Illinois, Ohio, Michigan, Pennsylvania, Colorado, and Nevada.